Trump Administration Announces Projected Savings From Drug Pricing Agreements

The piece appears in STAT’s The Readout newsletter, which offers a morning rundown of the science, politics, and money driving biotech.

The Trump administration’s savings projections come without public details on the specific deals or the methodology used to calculate future reductions in drug spending. Outside experts highlighted the absence of transparent data that would allow independent confirmation of the touted savings figures.

Accusations of political interference at the FDA center on recent drug review decisions that some stakeholders view as influenced by external pressures rather than purely scientific evidence.

The agency’s decision to reopen review of the rare cancer treatment follows internal and external pushback after the initial surprise rejection. Entrada’s next-generation Duchenne drug had been viewed as a potential advance over existing therapies. Its disappointing results represent a setback for the company and for patients awaiting new options in a disease with limited treatments.

U.S. rare disease market. The deal includes Catalyst’s portfolio of approved therapies and ongoing development programs.

Novo Nordisk’s update on its Wegovy pill provided relief to investors concerned about competition in the weight-loss drug space. The company’s earnings and share price rose following the release of data that were not as negative as some analysts had anticipated. The virtual AI cancer clinic initiatives seek to reduce the need for in-person visits while maintaining quality of care.

Startups are deploying AI to assist with monitoring, treatment planning, and patient management in oncology. Research into the “dark proteome” focuses on thousands of protein variants that standard biological databases have largely overlooked. Scientists hope the emerging data will reveal new mechanisms of disease and opportunities for drug development.